Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
NCT06626789

Brain Signal Training to Enhance Affect Down-regulation

Led by Central Institute of Mental Health, Mannheim · Updated on 2026-02-03

164

Participants Needed

6

Research Sites

162 weeks

Total Duration

On this page

Sponsors

C

Central Institute of Mental Health, Mannheim

Lead Sponsor

U

University Medical Center Freiburg

Collaborating Sponsor

AI-Summary

What this Trial Is About

Individuals with Borderline Personality Disorder (BPD) experience intensive, instable negative emotions. Hyperactivity of the amygdala is assumed to drive exaggerated emotional responses in BPD. Neurofeedback is an endogenous neuromodulation method to address the imbalance of neural circuits. Downregulation of amygdala hyperactivation with neurofeedback may ameliorate dysregulated emotions in BPD. The BrainSTEADy trial is designed to determine whether amygdala-fMRI-BOLD neurofeedback has a specific effect on affect instability in BPD beyond nonspecific benefit.

CONDITIONS

Official Title

Brain Signal Training to Enhance Affect Down-regulation

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged between 18 and 65 years
  • Diagnosed with Borderline Personality Disorder
  • Insufficient response to at least two therapies
  • Sufficient German language skills to give informed consent and complete study tasks
  • Able to understand the clinical investigation and its consequences
  • Written informed consent provided before enrollment
  • For women of childbearing potential, use of adequate contraception
Not Eligible

You will not qualify if you...

  • Use of benzodiazepines within 7 days before screening
  • Current alcohol or substance dependence
  • Diagnosis of psychotic disorder or schizophrenia at any time
  • Significant neurological conditions such as stroke, brain injury, or multiple sclerosis
  • Significant visual impairment interfering with study tasks
  • Changes in psychopharmacologic or psychological treatments within 2 weeks prior or during study
  • Neurofeedback treatment within 3 months prior or during study
  • Unable or unwilling to comply with study procedures
  • History of claustrophobia or inability to tolerate MRI scanner
  • Any MRI contraindications such as metal implants
  • Clinically relevant brain abnormalities on prior MRI
  • Planned medical treatments during study interfering with procedures
  • Significant risk of serious violence or suicide
  • Body mass index (BMI) of 16.5 or lower
  • Participation in other clinical or competing trials
  • Previous participation in this trial
  • Pregnancy or lactation
  • Institutionalization by legal or official order
  • Legal incapacity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

University clinic Freiburg

Freiburg im Breisgau, Germany, 79104

Actively Recruiting

2

University clinic Giessen

Giessen, Germany, 35392

Actively Recruiting

3

University Clinic Halle (Saale)

Halle, Germany

Not Yet Recruiting

4

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

Actively Recruiting

5

Central Institute of Mental Health

Mannheim, Germany, 68159

Actively Recruiting

6

University Clinic Tuebingen

Tübingen, Germany, 72076

Actively Recruiting

Loading map...

Research Team

C

Christian Paret-Voigt, Dr.

CONTACT

M

Miroslava Hofmanová

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here